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Nowadays, patients with chronic hepatitis C in all countries are generally treated with interferon (IFN), and more than 50% of
patients become HCV-RNA negative following PEG-IFN plus ribavirin therapy, but unfortunately, the IFN therapy is not eﬀective
in about 70% of patients with HCV-associated LC. In Japan, HCC actually develops in about 7% of those patients every year. A
strategy for preventing HCC development other than IFN therapy is, therefore, urgently needed for those patients. We reported
that the recurrence rate and the development of HCC was more rapid in the high serum ALT level (>80 IU) patients with HCV-
associated LC. Sho-saiko-to, Juzen-taiho-to, and stronger-neo minophagen C are herbal medicines used in Japan to treat chronic
viral liver diseases, and they work by reducing inﬂammatory processes and controlling ALT levels. Aggressive reduction therapy
for ALT levels in HCV-LC patients could signiﬁcantly prevent HCC development.
1.Introduction
Repeated inﬂammation and the resulting increased prolif-
eration (mitotic activity) of tissue cells are correlated with
the development of carcinoma, presumably by chromosomal
instability, an increased rate of random mutations [1, 2], and
promotion of tumor growth [3, 4]. There are many reported
clinical instances that demonstrate the relationship between
continuous inﬂammation and carcinogenesis: Helicobacter
pylori infection and gastric cancer [5], ulcerative colitis and
colorectal cancer [6], Clonorchis sinensis infection and cho-
langiocelluar carcinoma [7, 8], hepatitis C virus-(HCV-) as-
sociated liver cirrhosis (LC) and hepatocellular carcinoma
(HCC) [9], and so on.
Considering the above ﬁndings, it is possible that the
same mechanism is involved in the development of human
HCC and that the development of HCC is accelerated by
continuous inﬂammation in the liver of patients with HCV-
associated LC. However, it is widely accepted that ﬁbrosis
may accelerate the development of HCC in HCV-associated
liver diseases [10, 11].
2. Review
2.1. A Cut-Oﬀ Levels of ALT. In 1997 [12], we reported the
relationship between the recurrence of HCC and the serum
ALT level in hepatectomized patients with HCV-associated
cirrhosis and HCC. Patients in Group A had no recurrence 3
years after surgery, and patients in Group B recurred during
1–3yearsaftersurgery.Thepatients’serumALTlevelsduring
this period were examined. In Group A, serum ALT generally
showed sustained low levels <80IU in 80% patients. In con-
trast, ALT levels in Group B showed several peaks or plateaus
>80IU in 81.2% patients. Moreover, with regard to the ALT
levels, the recurrence rate of HCC in the hepatectomized
patientswithsustainedlowlevelsofALTwas14.3%at3years
and was signiﬁcantly lower (P<0.01) than that was 75.0%
in those patients whose ALT levels showed several peaks or
plateaus >80IU. The importance of hepatocytic necrosis
in the recurrence of HCC in hepatectomized patients with
cirrhosis and HCC of HCV origin was demonstrated and the
signiﬁcance of subsiding hepatic necroinﬂammatory process
in the prevention of HCC recurrence suggested. Because of2 ISRN Oncology
this results, serum ALT level 80IU was adopted as a cut-oﬀ
level.
2.2. ALT Levels and Development of HCC. In 1999 [13], we
reported association between high serum ALT levels and
more rapid development and high incidence of HCC in
patients with HCV-associated LC. In the paper, the correla-
tionbetweenthepersistentelevationofserumALTlevelsand
the development of HCC was studied in patients with early-
stage HCV-associated LC. Patients were subdivided into 2
groups according to their serum ALT levels: annual average
serum ALT levels of Group A were persistently high (≥80IU)
and that of Group B was persistently low (<80IU). HCC
developed in 71.4% of patients in Group A compared with
25.0% in Group B over the observation period (P<0.005).
The 5-year rate of incidence of HCC in Group A was as high
as 53.6% compared with only 7.1% in Group B (P<0.001).
The expected interval between the diagnosis of cirrhosis
and the development of HCC was 6.0 ± 0.7 years (mean ±
standard error (SE)) in Group A and 12.7 ± 1.2y e a r si n
Group B (P<0.001). The results demonstrated that the
development of HCC was more rapid in the high serum ALT
level patients with HCV-associated LC.
2.3. ALT Levels and Recurrence of HCC. In 2000 [14], we
investigated whether or not a high serum ALT level is
associated with a more rapid recurrence of HCC in hep-
atectomized patients with HCV-associated LC and HCC.
The hepatectomized patients with a single-nodule HCC had
no histologic evidence of portal or hepatic vein invasion.
They were subdivided into 2 groups according to their
serum ALT levels: serum ALT levels showed several peaks
or plateaus above 80IU were designated as Group A, and
serum ALT levels showed a sustained low level below 80IU
until ﬁrst recurrence were designated as Group B. In Group
A, HCC recurred within 3 years in 70.6% of patients. In
contrast, it recurred in only 18.8% in Group B in the same
period (P<0.05). There was a signiﬁcant diﬀerence
(P = 0.0201) between the two groups in the cumulative
nonrecurrence rate. The mean interval in recurrent patients
between hepatectomy and the ﬁrst recurrence in Group A
(23.6 ± 2.8 months) (mean ± SE) was signiﬁcantly (P<
0.02) shorter than that in Group B (49.3 ± 9.7 months). The
expected interval between hepatectomy and recurrence was
asshortas2.8±0.5years(mean ±SE)inGroupA,compared
with 5.8 ± 0.7y e a r si nG r o u pB( P<0.05). These results
showed that the recurrence of HCC was accelerated in the
high serum ALT level patients with HCV-associated LC.
2.4. Multicentric Hepatocarcinogenesis and Sustained High
ALT Levels. In 2002 [15], we investigated whether the per-
sistent elevation of the serum ALT level is correlated with
the multicentric development of HCC in patients with early-
stage HCV-associated LC. Ninety-three patients with biopsy-
proven HCV-associated LC (Child Stage A) were studied.
They were subdivided into three groups according to their
serum ALT level: Group A included 33 patients with an-
nual average serum ALT levels that were persistently high
(≥80IU), Group B included 41 patients with annual average
serum ALT levels that were persistently low (<80IU), and
Group C included 19 unclassiﬁed patients. The patients had
been studied prospectively with frequent ultrasonography
(US) and magnetic resonance imaging (MRI) or computed
tomography (CT) for recurrence for >5 years. When the
development of HCC was suspected, angiography, infusion
into the hepatic artery, and lipiodol-CT were performed in
all patients to determine the number of HCC nodules. In
Group A, 27 patients (81.8%) developed HCC. Seventeen
of 27 patients (63.0%) had multiple nodules. In contrast, in
Group B, only 12 patients (29.3%) developed HCC, and only
1 of 12 patients (8.3%) had multiple nodules. There were
signiﬁcant diﬀerences between Group A and B in the in-
cidence of developing HCC (P<0.001) and developing
multi-nodules (P = 0.006). In addition, among the male
patients, the incidence of developing multiple HCC nodules
in Group A (12 of 19 patients; 63.2%) was signiﬁcantly
higher(P<0.05)comparedwiththeincidenceinGroupB(0
of 6 patients; 0%). The same tendency was observed among
female patients. These results showed a close correlation
between multicentric hepatocarcinogenesis and sustained
necroinﬂammation of the liver in patients with early-stage
HCV-associated LC.
2.5. Low-ALT Levels and a Survival Advantage. In 2003 [16],
we reported whether sustained alleviation of inﬂammation
as monitored by serum ALT levels was associated with longer
survival in hepatectomized HCC patients with HCV-asso-
ciated LC. Thirty-four hepatectomized patients with HCV-
associated LC and HCC as a single nodule, for whom more
than 5 years had elapsed after the hepatectomy, were studied.
They had no histologic evidence of portal or hepatic vein
invasion. They were subdivided into two groups according
to their serum ALT levels in the 2 years after hepatectomy:
the low-ALT group comprised 13 patients whose serum ALT
levels showed a sustained low level below 80IU, and the
high-ALT group comprised 21 patients whose serum ALT
levels showed several peaks or plateaus above 80IU. The
patients had been followed up prospectively with frequent
US and MRI or CT for recurrence for >5y e a r s .T h es u r v i v a l
period, nonrecurrence interval, and number of recurrences
were observed. Recurrences were treated with transcatheter
chemoembolization in all cases. The cumulative survival rate
in the low-ALT group was signiﬁcantly better than that in
the high-ALT group (P< 0.05). The 5-year survival in the
low-ALT group was as high as 92.3% (12 of 13) compared
with 33.3% (7 of 21) in the high-ALT group (P<0 .05). The
cumulative nonrecurrence rate in the low-ALT group was
also signiﬁcantly better than that in the high-ALT group (P<
0 .01). The survival period correlated well with the interval
until the ﬁrst recurrence (r = 0.545, P = 0.006). There was
a tendency for the number of recurrences in the low-ALT
group (1.5 ± 0.4, mean ± SE) to be fewer than that in the
high-ALT group (2.2±0.4) although this was not signiﬁcant.
Sustained alleviation of inﬂammation, as indicated by low-
ALT levels, provides a survival advantage mainly due to the
longer nonrecurrence interval, and possibly because of fewerISRN Oncology 3
recurrences, in hepatectomized HCC patients with HCV-
associated LC.
2.6. Anti-Inﬂammatory Drugs. Previous our study suggested
that suppression of the rise in ALT level by treatment using
anti-inﬂammatory drugs may prolong the recurrent free in-
terval and decrease the rate of development of HCC in pa-
tients with HCV-associated LC.
In 2006 [17], we reported the reduction therapy of
serum ALT levels using herbal medicine. Sho-saiko-to [18],
Juzen-taiho-to, and stronger-neo minophagen C (SNMC;
glycyrrhizin [19]) are herbal medicines used in Japan to treat
chronic viral liver diseases, and they work by reducing
inﬂammatory processes and controlling ALT levels. Urso-
deoxycholic acid (UDCA) and protoporphyrin are also used
to suppress elevated ALT levels in some cases. Suzuki et al.
[19] demonstrated a signiﬁcant decrease in serum ALT levels
obtained by intravenous injection of SNMC in patients with
chronic hepatitis, and Hirayama et al. [20] showed a sig-
niﬁcant decrease in serum ALT levels obtained by oral ad-
ministration of Sho-saiko-to in patients with chronic active
hepatitis. Bellentani et al. [21] demonstrated a signiﬁcant
decreaseinserumALTlevelsobtainedbyoraladministration
ofUDCAinthelong-termtreatmentofpatientswithchronic
hepatitis. To ﬁnd a way to prevent the development of he-
patocellular carcinoma (HCC) from hepatitis-C-virus-asso-
ciated liver cirrhosis (HCV-LC), an analysis of the HCV-
LC patients who had reduction therapy of ALT levels was
performed. Seventy-four consecutive HCV-LC patients of
Child Stage A were followed for >10 years for the devel-
opment of HCC. They were divided into two groups: in
group A, the reduction therapy for ALT levels is aggressively
performed, and in group B, the reduction therapy was not
performed aggressively. The patients were subdivided into 3
subgroups according to their serum ALT levels. In groups
A and B, the high-ALT group was comprised, respectively,
of 9 and 5 patients whose annual average serum ALT level
was persistently high (≥80IU); the low-ALT group was com-
prisedof19and20patientswhoseannualaverageserumALT
levelwaspersistentlylow(<80IU),andtheremaining11and
10 patients had an annual average serum ALT level which
ﬂuctuated and was unclassiﬁed (unclassiﬁed group). In
group B, 65.7% of patients had developed HCC in 13 years,
in contrast to only 41.0% in group A (P = 0.039). In group
A, median HCC developing time was 12.8 years, in contract
to only 3.8 years in group B (P = 0.0013). Multivariate
analysis demonstrated that the mode of reduction therapy
and ALT levels were the signiﬁcant factors aﬀecting HCC
development. The chances of surviving for more than 10
years without developing HCC in the HCV-LC patients of
Child Stage A were far more favorable in group A than
in group B. These results suggest that aggressive reduction
therapyforALTlevelsinHCV-LCpatientscouldsigniﬁcantly
prevent HCC development.
2.7. High-ALT Levels Derived Carcinogens? In 2009 [22], to
assess retrospectively whether continuously high serum ALT
levels (≥80IU) in the ﬁrst three successive years after the
diagnosis of LC are predictive of a subsequent high incidence
of HCC in patients with Child Stage A HCV-associated LC.
The study comprised 132 HCV-associated LC (Child Stage
A) patients who had not received interferon therapy but
had been treated with anti-inﬂammatory agents [17]. At the
end of a 3-year followup after the diagnosis of LC, the pa-
tients were subdivided into three groups according to their
serum ALT levels, and the subsequent incidence of HCC was
assessed. The cumulative incidence of HCC starting from 3
years after the diagnosis of LC in the continuously high-ALT
group (annual average over 3 years always ≥80IU; n = 41;
GroupA)wasmarkedlyhigherthanthatinthecontinuously-
l o wA L Tg r o u p( a l w a y s<80IU; n = 48; Group B) (P<
0.005) during an observation period of 7.9 ± 3.7y e a r s .T h e
incidence of HCC in Group A was 11.8%/year. The odds
ratios of developing HCC in Group A and Group C (mixed
high and low ALT levels; n = 43) were 5.1-fold and 1.5-
fold that of Group B, respectively. A multivariate analysis
revealed that the ALT group was independently associated
with HCC development. Continuously high ALT levels for
three successive years following the diagnosis of LC can be
predictive of a very high incidence of HCC in Child A HCV-
associated LC patients.
The ﬁnal issue is the discussion of why the risk of de-
velopingHCCwasincreasedsomarkedlyinthecontinuously
high-ALT group, as demonstrated in our previous studies.
It is likely that genetic alterations accumulate rapidly as in-
ﬂammation persists and that the multistep process of car-
cinogenesis or promotion of tumor growth progresses more
rapidly in patients with continuously high ALT levels. In this
respect, Ferenc et al. [23] demonstrated signiﬁcant diﬀer-
ences in the P53 expression between mildly, moderately,
and severely inﬂamed biopsy samples in ulcerative colitis.
8-hydroxy-2 -deoxyguanosine (8-OHdG) is a promutagenic
DNA lesion produced by oxygen (hydroxy) radicals [24,
25], and is known to be a parameter of genetic risk for
hepatocarcinogenesis [26]. Furthermore, 8-OHdG was dem-
onstrated to be involved in the initiation of rat liver hepat-
ocarcinogenesis by low doses of N-nitrosodiethylamine [27].
Shimoda et al. [28] examined the levels of 8-OHdG in
patients with chronic hepatitis, LC, and HCC and found that
the OHdG level in liver aﬀected by chronic hepatitis was
signiﬁcantly higher than that in normal liver and that the
OHdG level in liver aﬀected by LC also tended to be higher
than that in normal liver. They also found a signiﬁcant cor-
relation between the OHdG content in noncancerous liver
tissue and individual serum ALT levels and concluded that
chronic inﬂammation in the liver might produce oxidative
DNA damage, which would increase the risk of genomic
alterations causing hepatocarcinogenesis. If high-grade in-
ﬂammation persists in the liver for many years, as in the con-
tinuouslyhigh-ALTgroupofpatientsinourreports,thelevel
of 8-OHdG might be high throughout the cirrhotic liver,
resulting in the development of HCC.
2.8. The Reason that Our Aggressive Reduction Therapy
of ALT Reduced HCC Development. Shiota et al. reported
that Sho-Saiko-to prevents the development of HCC, and4 ISRN Oncology
suppression of 8-OHdG formation may be the leading cause
for inhibition of hepatocarcinogenesis by Sho-Saiko-to [26].
And Tsuchiya et al. reported that Juzen-taiho-to inhibited
the development of liver tumors reduced oxidative DNA
damage, inﬂammatory cell inﬁltration, and cytokine expres-
sion in mice [29]. These studies presented new important
information on the anticancer eﬀect of Sho-saiko-to and
Juzen-taiho-to in human and provided mechanistic evidence
that the protective eﬀects are, at least in part, due to re-
duction in oxidant and cytokine production by Kupﬀer cells.
These studies explain well the reason that our aggressive re-
duction therapy of ALT reduced HCC development.
Nowadays, patients with chronic hepatitis C in all coun-
tries are generally treated with interferon (IFN), and more
than 50% of patients become HCV-RNA negative following
PEG-IFN plus ribavirin therapy, but unfortunately, the IFN
therapy is not eﬀective in about 70% of patients with HCV-
associated LC. Moreover, patients with HCV-associated LC
carry a high risk of HCC, and in Japan, HCC actually de-
velopsinabout7%ofthosepatientseveryyear[4].Astrategy
for preventing HCC development other than IFN therapy is,
therefore, urgently needed for those patients.
3. Conclusion
We demonstrated that if the serum ALT level was high
(≥80IU), then the risk of recurrence of HCC in hepate-
ctomized patients and more rapid development of HCC
increased markedly as compared with the continuously low-
ALTgroupinChildAHCV-associatedLCpatients.However,
prospective trials using therapeutic approaches to decrease
ALT levels are necessary to conﬁrm a positive impact of ALT
reduction on the incidence of HCC in patients with HCV-
associated LC. Our studies suggest that serum ALT levels in
HCV-LC patients must be lowered to below 80IU by anti-
inﬂammatory drugs as soon as a diagnosis of LC is con-
ﬁrmed.
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